A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 After Single and Repeated Oral Dosing in Healthy Volunteers Using a Dose-Escalating, Randomized, Placebo-Controlled Study Design.
Phase of Trial: Phase I
Latest Information Update: 15 May 2017
At a glance
- Drugs GSK 1399686 (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 30 Sep 2009 Actual patient number (87) added as reported by ClinicalTrials.gov.
- 30 Sep 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 30 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.